Real-life reliability of plasma pTau181, A?(42)/A?(40), and pTau181/A?(42) measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status. in Journal of Alzheimer's disease : JAD / J Alzheimers Dis. 2025 Jan;103(1):305-315. doi: 10.1177/13872877241300315. Epub 2024 Dec 3.

2025
AO Cuneo
ASL Alessandria
ASL Cuneo 1
ASL Città di Torino

Tipo pubblicazione

Journal Article

Autori/Collaboratori (20)Vedi tutti...

Bozzali M
Dipartimento di Neuroscienze - Università di Torino, Ospedale Molinette, Torino, Italy.
Lopiano L
Dipartimento di Neuroscienze - Università di Torino, Ospedale Molinette, Torino, Italy.
Ferrandi D
SC Neurologia, Ospedale S. Croce, Moncalieri, Italy.

et alii...

Abstract

BACKGROUND: Alzheimer's disease (AD) is the most common neurodegenerative dementia, with diagnosis traditionally reliant on clinical criteria. Cerebrospinal fluid (CSF) biomarkers like pTau181 and A?(42)/A?(40) ratio significantly improve diagnostic accuracy but are invasive. Plasma biomarkers measured by automated assays offer a non-invasive alternative. OBJECTIVE: To evaluate the diagnostic performance of plasma pTau181, A?(42)/A?(40), and pTau181/A?(42) ratios in predicting CSF amyloid status in a real-life clinical setting. METHODS: Data from consecutive patients whose plasma and CSF samples sent to our laboratory between March and October 2022, were retrospectively analyzed. Plasma and CSF pTau181, A?(42), and A?(40) levels were measured using the Lumipulse G600II platform. CSF amyloid status was classified as amyloid-positive (A+) or amyloid-negative (A-) based on the A?(42)/A?(40) ratio. Statistical analyses included Spearman correlation, receiver operating characteristic (ROC) curves, and multivariate logistic regression to evaluate biomarker performance. RESULTS: Among 165 individuals (83 females), 29.1% were classified as A+. Significant correlations were found between plasma and CSF biomarkers, with the highest for the pTau181/A?(42) ratio (?=0.620, p?